{"id":"W2495512985","doi":"10.1200/jco.2016.34.4_suppl.192","title":"Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"ca_institutions":"Baker Hughes (Canada); Ottawa Hospital; McGill University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sorafenib; Clinical endpoint; Interim analysis; Hazard ratio; Hepatocellular carcinoma; Internal medicine; Randomized controlled trial; Phases of clinical research; Oncology; Gastroenterology; Progression-free survival; Surgery; Chemotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042261,0.002404822,0.002887036,0.0007763493,0.0004954066,0.001209517,0.001192874,0.001801959,0.00833883],"category_scores_gemma":[0.002571139,0.001033265,0.001564311,0.0006510234,0.001738561,0.000961724,0.000841446,0.003472698,0.001624607],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001675246,"about_ca_system_score_gemma":0.003004793,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003395807,"about_ca_topic_score_gemma":0.00797832,"domain_scores_codex":[0.9989592,0.0006919174,0.00003353339,0.000113097,0.00006433963,0.0001379009],"domain_scores_gemma":[0.9985575,0.0003103307,0.0002636761,0.0001048139,0.00008066991,0.0006829258],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9781058,0.008293581,0.0007879345,0.0002331095,0.0004449135,0.00003396114,0.00004841466,0.0005574087,0.001906621,0.0001053569,0.001917782,0.007565152],"study_design_scores_gemma":[0.9714174,0.026581,0.0008053796,0.000009128209,0.000120321,0.00001709293,0.00001083183,0.0003492364,0.000125129,0.00008833457,0.0004685105,0.000007638034],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9730878,0.002439952,0.0009850028,0.002485413,0.0007208823,0.01282234,0.003420689,0.0002376251,0.00380029],"genre_scores_gemma":[0.963959,0.002034159,0.003544969,0.004110193,0.0005096322,0.01497082,0.003617187,0.00006183868,0.00719214],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00833883,"threshold_uncertainty_score":0.02789617,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09144095418322526,"score_gpt":0.4539521059192045,"score_spread":0.3625111517359793,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}